Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by BidaskClub

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, BidAskClub reports.

Several other research firms also recently weighed in on VYGR. Wedbush restated a “buy” rating and set a $24.00 price target on shares of Voyager Therapeutics in a research report on Wednesday, August 12th. HC Wainwright reduced their target price on Voyager Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $15.00 price target on shares of Voyager Therapeutics in a research note on Friday, August 14th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $16.75.

Shares of NASDAQ:VYGR opened at $10.90 on Thursday. Voyager Therapeutics has a 1 year low of $6.26 and a 1 year high of $18.80. The firm has a market capitalization of $408.00 million, a price-to-earnings ratio of -6.65 and a beta of 1.79. The business’s 50 day moving average price is $11.23 and its 200-day moving average price is $11.27.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.52. The company had revenue of $28.68 million during the quarter, compared to analyst estimates of $16.19 million. Voyager Therapeutics had a negative net margin of 60.61% and a negative return on equity of 66.46%. As a group, analysts forecast that Voyager Therapeutics will post -1.61 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Clearbridge Investments LLC raised its stake in Voyager Therapeutics by 19.4% during the first quarter. Clearbridge Investments LLC now owns 1,208,675 shares of the company’s stock worth $11,059,000 after purchasing an additional 196,342 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 17.8% during the 1st quarter. Wells Fargo & Company MN now owns 457,906 shares of the company’s stock worth $4,191,000 after buying an additional 69,335 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Voyager Therapeutics by 13.7% during the 1st quarter. BlackRock Inc. now owns 2,407,352 shares of the company’s stock worth $22,029,000 after buying an additional 290,158 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Voyager Therapeutics by 454.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 15,432 shares of the company’s stock valued at $141,000 after buying an additional 12,648 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Voyager Therapeutics by 11.1% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 26,400 shares of the company’s stock valued at $242,000 after acquiring an additional 2,637 shares during the last quarter. 78.79% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: What is the float in trading stocks?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.